Security News
FDA and EMA Accept Teva’s Omalizumab Biosimilar Applications
UnknownApr 15, 2026(27 days ago)
FDA and EMA Accept Teva’s Omalizumab Biosimilar Applications
On March 30, 2026, Teva announced that the FDA and the European Medicines Agency (EMA) accepted regulatory submissions for its proposed biosimilar to Xolair® (omalizumab), TEV-45779.... By: Venable LLP